Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies
Cancers · 17.11.2026 · 18 (22) · 3673
DOI: 10.3390/cancers18223673 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 17.11.2026. Verfasst von Katharina Leitner und 8 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: DESTINY-PanTumor02 demonstrated clinically meaningful activity of trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, including gynecologic cancers, contributing to regulatory approval for unresectable or metastatic HER2 immunohistochemistry (IHC) 3+ solid tumors. Evidence in gynecologic malignancies with low HER2 expression remains limited. We evaluated T-DXd in a predominantly HER2-low, heavily pretreated population.
Methods
This retrospective, single-center cohort study included 11 patients with recurrent gynecologic malignancies who initiated therapy with T-DXd at the Medical University of Innsbruck between January 2024 and February 2026 following progression on standard-of-care treatment. The cohort comprised patients with ovarian (n = 6), endometrial (n = 2), and cervical cancer (n = 3). Treatment response, survival outcomes, and adverse events were assessed.
Results
Among 11 heavily pretreated patients, seven (64%) had tumors with HER2 IHC 1+, three (27%) had HER2 IHC 2+/ISH negative, and one (9%) had HER2 IHC 3+ expression. The overall response rate was 67% (6/9; 95% CI 29.9–92.5) and disease control rate was 78% (7/9; 95% CI 40.0–97.2). Kaplan–Meier median duration of response was 4.6 months (95% CI, 1.9–7.3), with two responses ongoing at 8.7 and 20.1 months. Median progression-free and overall survival were 7.0 months (95% CI, 1.6–12.4) and 12.0 months (95% CI, 8.3–15.7), respectively. Treatment-associated adverse events occurred in 73% of patients, including interstitial lung disease in two patients.
Conclusions
T-DXd showed antitumor activity in this predominantly HER2-low real-world cohort. These findings support further clinical investigation of T-DXd in patients with low HER2 expressing gynecological malignancies.
Zitieren
APA
Leitner, K., Tsibulak, I., Ebner, C., Feroz, B., Steger, K., Sprung, S., Marth, C., Alkatout, I., & Wieser, V. (2026). Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies. Cancers, 18(22), 3673. https://doi.org/10.3390/cancers18223673
Vancouver
Leitner K, Tsibulak I, Ebner C, Feroz B, Steger K, Sprung S, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies. Cancers. 2026;18(22):3673. doi:10.3390/cancers18223673
BibTeX
@article{Leitner2026,
author = {Leitner, Katharina and Tsibulak, Irina and Ebner, Christoph and Feroz, Barin and Steger, Katharina and Sprung, Susanne and Marth, Christian and Alkatout, Ibrahim and Wieser, Verena},
title = {Efficacy and Safety of Trastuzumab Deruxtecan in Heavily Pretreated Predominantly Low HER2 Expressing Gynecologic Malignancies},
journal = {Cancers},
year = {2026},
volume = {18},
number = {22},
pages = {3673},
doi = {10.3390/cancers18223673}
}
EUVIMED